Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

25.33 +0.32 (+1.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Lost Money on Pacira BioSciences, Inc.(PCRX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
Via ACCESSWIRE
News headline image
Shareholder Rights Advocates at Levi & Korsinsky Investigate Pacira BioSciences, Inc. (PCRX) Regarding Possible Securities Fraud Violations
Via ACCESSWIRE
News headline image
Pacira BioSciences, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Pacira BioSciences, Inc. (PCRX)
Via ACCESSWIRE
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Awarded New U.S. Patent Covering EXPAREL Composition
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
-- Poster to be presented at ACR Convergence annual meeting -- 
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Third Quarter 2024 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience 
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Second Quarter 2024 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
From Pacira BioSciences
Via GlobeNewswire
News headline image
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
Via AB Newswire
Topics Death
News headline image
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
From Pacira BioSciences
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.